reviewed april 2026|next review october 2026|88 physicians psi has verified|3 published studies
Palmitoyl Tripeptide-1
Palmitoyl tripeptide-1 (Pal-GHK) is a palmitoylated version of the GHK tripeptide sequence without copper, functioning as a matrikine signal peptide typically formulated with palmitoyl tetrapeptide-7 as the combination product Matrixyl 3000.
Evidence landscape: 3 published studies
0 published items under this slug.
- 3 Other research
The same Gly-His-Lys backbone as GHK-Cu but without copper binding and with a palmitic acid chain for skin penetration. Signal peptide activity only, not the broad gene modulation associated with the copper complex.
Typically formulated in combination with palmitoyl tetrapeptide-7 as Matrixyl 3000, developed by Sederma (now Ashland). Most clinical data is for the combination product, not the individual peptide.
Zero published studies under this specific compound name in major databases. The evidence base is borrowed from GHK biology and the Matrixyl 3000 combination.
PSI Assessment
Palmitoyl tripeptide-1 sits between two well-studied compounds: GHK-Cu (the copper-bound form with 186 studies) and Matrixyl 3000 (the combination product with manufacturer clinical data). The individual peptide has the same GHK backbone but without copper, meaning it retains matrikine signaling activity but loses the copper delivery mechanism that drives much of GHK-Cu's documented gene modulation. Most evidence for this compound is inherited from the Matrixyl 3000 combination or the broader GHK literature. Published studies under this specific name are absent from major databases.
Same GHK backbone as GHK-Cu but without copper and with a fatty acid chain. Part of Matrixyl 3000. Signal peptide activity only, not the broad gene modulation of GHK-Cu.
Palmitoyl tripeptide-1 (Pal-Gly-His-Lys) is a lipopeptide consisting of the GHK tripeptide sequence conjugated to palmitic acid. Without copper, it functions as a matrikine signal peptide, mimicking collagen breakdown fragments to stimulate TGF-beta signaling and collagen production in fibroblasts. It is most commonly found as part of the Matrixyl 3000 formulation (developed by Sederma/Ashland), where it is combined with palmitoyl tetrapeptide-7. The palmitoyl chain enhances penetration through the stratum corneum. Independent evidence for this specific peptide, separate from the combination product or from GHK-Cu, is essentially absent.
What the evidence supports
Palmitoyl tripeptide-1 is a palmitoylated GHK sequence that enhances skin penetration through the lipid barrier. The matrikine signaling mechanism stimulates TGF-beta and collagen production in cell culture. Commercial success as part of the Matrixyl 3000 formulation.
What is not yet established
Published studies under this specific compound name. Whether the palmitoylated GHK without copper delivers meaningful skin benefits independent of the Matrixyl 3000 combination. Comparative efficacy against GHK-Cu. Independent academic validation.
Research Evidence
The findings below cover the GHK relationship, the Matrixyl 3000 context, and the limited evidence for the individual peptide.
Evidence by condition
Evidence dimensions for palmitoyl tripeptide-1. All evidence is inherited from GHK biology and the Matrixyl 3000 combination. No dedicated studies for this individual peptide.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Skin Aging | ||||
| Collagen Production | ||||
| Wound Healing Signal |
Palmitoyl tripeptide-1 shares the GHK backbone with GHK-Cu. The matrikine signaling mechanism (stimulating TGF-beta and collagen production) is established for the GHK sequence in cell culture.
The GHK biology is well-characterized. Whether palmitoylated GHK without copper retains meaningful biological activity independent of the copper delivery mechanism is not established by dedicated studies.
The Matrixyl 3000 combination product (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) has manufacturer-sponsored studies reporting wrinkle reduction and collagen stimulation.
These results cannot be attributed to palmitoyl tripeptide-1 alone. The contribution of each component to the combination product's effects is not characterized.
Zero published studies appear under this specific compound name in major databases. The evidence base is entirely inherited from GHK research and Matrixyl 3000 combination data.
This is the central limitation. The compound is commercially widespread but scientifically uncharacterized as an individual ingredient.
How Palmitoyl Tripeptide-1 Works
Palmitoyl tripeptide-1 (Pal-GHK) is a palmitoylated version of the GHK tripeptide that functions as a matrikine signal peptide, stimulating TGF-beta signaling and collagen production without the copper delivery mechanism of GHK-Cu.
Mimics a collagen breakdown fragment that signals skin cells to produce more collagen.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Palmitoylated GHK analog activating TGF-beta signaling. Stimulates collagen I, III, fibronectin.
What is Palmitoyl Tripeptide-1 being studied for?
Researchers are studying Palmitoyl Tripeptide-1 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Palmitoyl Tripeptide-1 overall. This means a compound can have human studies for one condition but only animal data for another.
Skin Aging
·Animal StudiesThe GHK matrikine mechanism is established. The Matrixyl 3000 combination (containing this peptide) has manufacturer data supporting anti-aging effects.
Limitations: No studies specific to this individual peptide. All evidence inherited from GHK biology or the combination product. Comparative efficacy against GHK-Cu is not established.
Collagen Production
·Animal StudiesGHK sequences stimulate collagen production in fibroblast cultures. Palmitoylation enhances skin penetration.
Limitations: Whether palmitoylated GHK without copper produces meaningful collagen stimulation independent of the Matrixyl 3000 combination is not established.
Wound Healing Signal
·PreclinicalGHK is a matrikine released during collagen degradation. The wound-healing signaling concept is established for the GHK sequence.
Limitations: No wound-healing data specific to the palmitoylated form. The copper delivery mechanism absent from this form is central to GHK-Cu's wound-healing evidence.
Safety and Regulatory Status
FDA Status: Not a regulated pharmaceutical. Marketed as a cosmetic ingredient.
Availability: Widely available as part of the Matrixyl 3000 complex in over-the-counter skincare products.
Class context: Palmitoylated matrikine signal peptide. Same GHK backbone as GHK-Cu but without copper. Part of the copper peptide family in a modified form.
Excellent topical safety profile as part of the Matrixyl 3000 formulation. Non-irritating and non-sensitizing. Gentler than retinoids.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Palmitoyl Tripeptide-1 discussion.
Comparison and Related Research
Palmitoyl tripeptide-1 is most often compared with GHK-Cu (copper-bound form with broader mechanism), Matrixyl (pentapeptide matrikine), and tripeptide-1 (unmodified GHK without palmitoylation).
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Comprehensive review of cosmeceutical peptides including palmitoyl tripeptide-1 (Pal-GHK). The paper covered the matrikine signaling mechanism, palmitoylation for enhanced skin penetration, and the Matrixyl 3000 combination product developed by Sederma.Lintner K et al., 2009 in Int J Cosmet Sci. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.